Benchmark Litigation is part of Legal Benchmarking Limited, 1-2 Paris Garden, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

Omar Jafri

Pomerantz

2027_BM US_Future Star.svg
Position: Partner
Rating:
  • Future Star
Jurisdictions:
Biography
Omar Jafri is a Partner at Pomerantz, where he advocates for defrauded investors in both individual and class action securities litigation. Omar has been honored by Lawdragon as one of the 500 Global Plaintiff Lawyers and a Leading Plaintiff Financial Lawyer in the United States. He is also recognized as a Top-Rated Securities Litigator by Super Lawyers®. He was named a Rising Star of the Plaintiffs’ Bar by the National Law Journal, an honor bestowed on select lawyers who “demonstrated repeated success in cutting-edge work on behalf of plaintiffs over the last 18 months [and] possess a solid track record of client wins over the past three to five years.” Additionally, Super Lawyers® honored him as a Rising Star in Securities Litigation from 2021 to 2023.

Omar has been instrumental as Lead, Co-Lead, or Additional Counsel in numerous cases, contributing to substantial recoveries for defrauded shareholders. He played an integral role in Roofer’s Pension Fund v. Papa et al. ($97 million recovery); Glazer Capital Management, L.P. et al. v. Forescout Technologies, Inc. et al. ($45 million recovery); In re Chicago Bridge & Iron Co. N.V. Securities Litigation ($44 million recovery); In re Juno Therapeutics, Inc. Securities Litigation ($24 million recovery); In re Aveo Pharmaceuticals, Inc. Securities Litigation ($18 million recovery); Sudunagunta v. NantKwest, Inc. ($12 million settlement); Cooper v. Thoratec Corporation et al. ($11.9 million settlement); Felipe v. Playstudios, Inc. et al. ($6.5 million settlement); Thomas v. MagnaChip Semiconductor Corp. Securities Litigation ($6.2 million settlement); Solomon v. Sprint Corporation et al. ($3.75 million settlement); In re Paysign, Inc. Securities Litigation ($3.75 million settlement); Schaeffer v. Nabriva Therapeutics plc et al. ($3 million settlement); In re Sequans Communications S.A. Securities Litigation ($2.75 million settlement); Torres et al. v. Berry Corporation et al. ($2.5 million settlement); and Busic v. Orphazyme A/S et al. ($2.5 million settlement).